Corrigendum to 'A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report' [Eur J of Canc (2017) 206–225]
| Autor: | Astrid K. Gnekow, David A. Walker, Daniela Kandels, Susan Picton, null Giorgio Perilongo, Jacques Grill, Tore Stokland, Per Eric Sandstrom, Monika Warmuth-Metz, Torsten Pietsch, Felice Giangaspero, René Schmidt, Andreas Faldum, Denise Kilmartin, Angela De Paoli, Gian Luca De Salvo, Irene Slavc, Giorgio Perilongo, Sue Picton, David Walker, Per Erik Sandstrom, Niels Clausen, Mikko Arola, Olafur Gisli Jonsson, Ofelia Cruz, Aurora Navajas, Anna Teijeiro, Chantal Kalifa, Marie-Anne Raquin, Joris Verlooy, Volkmar Hans, Wolfram Scheurlen, Johannes Hainfellner, James Ironside, Keith Robson, Kari Skullerud, David Scheie, null NN, Marie-Madeleine Ruchoux, Anne Jouvet, Dominique Figarella-Branger, Arielle Lellouch-Toubiana, Daniela Prayer, Milena Calderone, Tim Jaspan, Soren Jacob Bakke, Eli Vazquez, Dominique Couanet, Rolf D. Kortmann, Karin Diekmann, Giovanni Scarzello, Roger Taylor, Knut Lote, Jordi Giralt, Christian Carrie, Jean Louis Habrand, Niels Soerensen, Thomas Czech, Paul Chumas, Bengt Gustavson, Michel Zerah, Bettina Wabbels, Maria Luisa Pinello, Alistair Fielder, Ian Simmons, Terje Christoffersen, Gabriele Calaminus, Knut Brockmann, Ronald Straeter, Friedrich Ebinger, Pablo Hernaiz-Driever, Herwig Lackner, Colin Kennedy, Adam Glaser, Bo Stromberg, Jose Ma Indiano, Chantal Rodary, Eric Bouffet, Didier Frappaz, Angela Emser, Suzanne Stephens, David Machin, Marie-Cécile Le Deley, Thore Egeland, Carolyn Freemann, Martin Schrappe, Richard Sposto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Vincristine Article Carboplatin law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Child Etoposide Cancer och onkologi Brain Neoplasms business.industry Infant Glioma Induction Chemotherapy Survival Analysis 030104 developmental biology chemistry Child Preschool 030220 oncology & carcinogenesis Cancer and Oncology Female Low-Grade Glioma business medicine.drug |
| Zdroj: | European Journal of Cancer |
| Popis: | The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus four-drug regimens with a duration of 12 months of treatment after resection.Within the European comprehensive treatment strategy for childhood LGG, the International Society of Paediatric Oncology-Low Grade Glioma (SIOP LGG) Committee launched a randomised trial involving 118 institutions and 11 countries to investigate the addition of etoposide (100 mg/mNo differences between the two arms were found in term of survival and radiological response. Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively. Age and diencephalic syndrome are adverse clinical risk factors for PFS and OS. 5-year OS for patients in early progression at week 24 were 46% (StDev 13.8) and 49% (StDev 16.5) in the two arms, respectively.The addition of etoposide to VC did not improve PFS or OS. High non-progression rates at 24 weeks justify retaining VC as standard first-line therapy. Infants with diencephalic syndrome and early progression need new treatments to be tested. Future trials should use neurological/visual and toxicity outcomes and be designed to discriminate between the impact on disease outcomes of 'duration of therapy' and 'age at stopping therapy'. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|